GSA Capital Partners’s aTyr Pharma ATYR Stock Holding History

GSA Capital Partners’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.06M	Buy	3,454,863 +1,770,277	+105%	+$1.16M	0.13%	152
2026 Q1	$1.31M	Sell	1,684,586 -946,052	-36%	-$799K	0.08%	348
2025 Q4	$2.06M	Buy	2,630,638 +1,923,907	+272%	+$1.58M	0.18%	77
2025 Q3	$510K	Buy	706,731 +210,442	+42%	+$954K	0.04%	839
2025 Q2	$2.52M	Buy	496,289 +163,965	+49%	+$645K	0.18%	72
2025 Q1	$1M	Buy	332,324 +57,898	+21%	+$211K	0.09%	340
2024 Q4	$993K	Sell	274,426 -12,174	-4%	-$36.9K	0.07%	417
2024 Q3	$504K	Sell	286,600 -35,860	-11%	-$65.2K	0.04%	902
2024 Q2	$503K	Buy	322,460 +98,313	+44%	+$171K	0.04%	962
2024 Q1	$437K	Buy	224,147 +114,983	+105%	+$201K	0.03%	970
2023 Q4	$154K	Buy	109,164 +81,605	+296%	+$105K	0.01%	1366
2023 Q3	$44K	Buy	+27,559	New	+$51K	﹤0.01%	1423
2022 Q1	–	Sell	-58,791	Closed	-$439K	–	1914
2021 Q4	$439K	Buy	+58,791	New	+$491K	0.06%	686
2016 Q3	–	Sell	-2,607	Closed	-$101K	–	2008
2016 Q2	$101K	Buy	+2,607	New	+$121K	0.01%	1667

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

GSA Capital Partners's ATYR Position: Q2 2026 in Review

GSA Capital Partners increased its aTyr Pharma (ATYR) stake by 105% in Q2 2026, buying an estimated $1.16M and bringing the position to 3,454,863 shares worth $2.06M. The position accounts for 0.13% of the portfolio, ranked #152.

GSA Capital Partners first reported a position in ATYR in Q2 2016 and has held it in 14 quarters since. The position peaked at $2.52M in Q2 2025. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

GSA Capital Partners held 3,454,863 shares of aTyr Pharma worth $2.06M as of Q2 2026.
GSA Capital Partners bought 1,770,277 aTyr Pharma shares in Q2 2026, an estimated $1.16M.
aTyr Pharma made up 0.13% of GSA Capital Partners's portfolio in Q2 2026, its #152 holding.
GSA Capital Partners first reported a position in aTyr Pharma in Q2 2016 and has held it in 14 quarters since.
GSA Capital Partners's aTyr Pharma position peaked at $2.52M in Q2 2025.
90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.